Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 15/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955454 | 0.77 | LPAR1 (0.47) | — | |
| SCHEMBL21233196 | 0.75 | CYP11B2 (0.47) | GPR35ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL9955571 | 0.74 | SMN1; SMN2 (0.49) | KDR | |
| SCHEMBL1777658 | 0.73 | LPAR1 (0.42) | — | |
| SCHEMBL22952421 | 0.71 | ACVR1 (0.37) | AKT1AKT2BMPR1BKDRBMPR1A | |
| SCHEMBL9697757 | 0.70 | PKM (0.41) | — | |
| SCHEMBL9956226 | 0.70 | PTGS2 (0.58) | ROCK2ROCK1KDR | |
| SCHEMBL1357879 | 0.69 | HTT (0.50) | — | |
| SCHEMBL9956557 | 0.68 | PLK4 (0.44) | ROCK2ROCK1KDR | |
| SCHEMBL27926208 | 0.68 | LPAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | GPR35 3233/4885ROCK2 3627/4885ROCK1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.